The Advanced Photon Source
a U.S. Department of Energy Office of Science User Facility

How HIV Avoids Getting ZAPped

The original University of Michigan press release by Emily Kagey can be read here.

Humans have evolved dynamic defense mechanisms against the viruses that seek to infect our bodies—proteins that specialize in identifying, capturing and destroying the genetic material that viruses try to sneak into our cells. A new study, based upon research at the U.S. Department of Energy’s Advanced Photon Source (APS) and published in the Proceedings of the National Academy of Sciences of the United States of America, now reveals not only how one of these proteins latches onto foreign invaders, but also how some viruses—including the human immunodeficiency virus—evade capture. Revealing the precise mechanism that makes this protein an effective antiviral in some cases is a critical first step in the path toward better methods for attacking viruses that manage to dodge it.

The protein in question, called ZAP (short for zinc-finger antiviral protein), is made by cells to restrict a virus from replicating and spreading infection. When cells detect a virus, the ZAP gene is turned on and produces more of the protein. ZAP then singles out the virus’s genetic material, RNA, from the cell’s native RNA and targets the viral RNA for destruction.

A team of researchers from the University of Michigan (U-M) Life Sciences Institute (LSI) and Rockefeller University wanted to determine how ZAP recognizes the virus’s genome, and how some viruses avoid it. A previous study from Rockefeller revealed that ZAP grabs onto only one specific sequence of neighboring nucleotides (the building blocks of DNA and RNA): a cytosine followed by a guanine, or a CG dinucleotide. Human RNAs have few CG dinucleotides, and HIV RNA has evolved to mimic this characteristic.

“The main motivation for the study was, ‘How does HIV avoid this antiviral protein?'” said Jennifer Meagher, a researcher at U-M’s LSI and one of the lead authors of the study. “And because we’re structural biologists, we wanted to determine how ZAP ‘sees’ a CG dinucleotide—and how, structurally, it binds the RNA.”

Using a piece of viral RNA that was genetically altered to include extra CG sequences, Meagher and her colleagues at U-M used the Life Sciences Collaborative Access Team 21-ID-D x-ray beamline at the APS to determine the structure of the ZAP protein bound to RNA, exposing the mechanisms that enable the protein to be so selective. The APS is an Office of Science user facility at Argonne National Laboratory.

The researchers discovered that ZAP binds to the viral RNA at only one of the four “zinc fingers” on the protein that they considered potential binding sites. They further demonstrated that even a tiny change to that one binding site—altering just a single atom—hampered ZAP’s binding ability.

Working in cells, researchers from Rockefeller University found similar results when they altered ZAP’s composition. They created mutant versions of ZAP that were expressed in cells infected with either normal HIV or a version of the virus enriched with CG sequences.

The mutant ZAP proteins were less able to recognize CG-enriched regions of the viral RNA in cells. They also exhibited increased binding to areas of the RNA that were not rich in CG dinucleotides, indicating that alterations impair ZAP’s ability to distinguish viral RNA from human RNA.

“Natural selection appears to have shaped the ZAP protein structure in such a way to optimize the discrimination of nonself from self RNA, based on CG dinucleotide content,” said Paul Bieniasz, Howard Hughes Medical Institute investigator and head of the Laboratory of Retrovirology at Rockefeller. “However, successful viruses are often one step ahead in a molecular arms race.”

“This is the crucial first step in a complicated story of how the cell eventually degrades the virus’s RNA,” said Janet Smith, an LSI research professor and professor of biological chemistry at the U-M Medical School and Scientific Director of the National Institute of General Medical Sciences and National Cancer Institute structural biology facility at Sector 23 of the APS. “And now we know how the step is executed, and why it is not effective on HIV and other viruses that lack this CG sequence.”

See: Jennifer L. Meagher1, Matthew Takata2, Daniel Gonçalves-Carneiro2, Sarah C. Keane1, Antoine Rebendenne2, Heley Ong2, Victoria K. Orr1, Margaret R. MacDonald2, Jeanne A. Stuckey1, Paul D. Bieniasz2**, and Janet L. Smith1*, “Structure of the zinc-finger antiviral protein in complex with RNA reveals a mechanism for selective targeting of CG-rich viral sequences,” Proc. Nat. Acad. Sci. U.S.A., first published November 12, 2019. DOI: 10.1073/pnas.1913232116

Author affiliations: 1University of Michigan, 2The Rockefeller University

Correspondence: *JanetSmith@umich.edu, **pbieniasz@rockefeller.edu

This work was supported by the Center for HIV RNA studies (U54AI50470, formerly U54GM103297) and National Institutes of Health grant R01AI50111 to P.D.B. Use of the Life Sciences Collaborative Access Team was supported by the Michigan Economic Development Corporation and the Michigan Technology Tri-Corridor (Grant 085P1000817). This research used resources of the Advanced Light Source, a DOE Office of Science User Facility under contract no. DE-AC02-05CH11231, and the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357.

Argonne National Laboratory seeks solutions to pressing national problems in science and technology. The nation's first national laboratory, Argonne conducts leading-edge basic and applied scientific research in virtually every scientific discipline. Argonne researchers work closely with researchers from hundreds of companies, universities, and federal, state and municipal agencies to help them solve their specific problems, advance America's scientific leadership and prepare the nation for a better future. With employees from more than 60 nations, Argonne is managed by UChicago Argonne, LLC, for the U.S. DOE Office of Science.

The U.S. Department of Energy's Office of Science is the single largest supporter of basic research in the physical sciences in the United States and is working to address some of the most pressing challenges of our time. For more information, visit the Office of Science website.

Published Date
11.13.2019